Peroxisome proliferator-activated receptor α gene variants influence progression of coronary atherosclerosis and risk of coronary artery disease

Circulation

Volumn 105, Issue 12, 2002, Pages 1440-1445

  Flavell, David M ^a   Jamshidi, Yalda ^a   Hawe, Emma ^a   Pineda Torra, Inés ^a   Taskinen, Marja Riitta ^a   Frick, M Heikki ^a   Nieminen, Markku S ^a   Kesäniemi, Y Antero ^a   Pasternack, Amos ^a   Staels, Bart ^a   Miller, George ^a   Humphries, Steve E ^a   Talmud, Philippa J ^a   Syvänne, Mikko ^a  

^a ROYAL FREE AND UNIVERSITY COLLEGE MEDICAL SCHOOL   (United Kingdom)

Author keywords

Atherosclerosis; Coronary disease; Genetics

Indexed keywords

APOLIPOPROTEIN A1; APOLIPOPROTEIN B; CHOLESTEROL; CYTOSINE; GEMFIBROZIL; GUANINE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LEUCINE; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA; TRIACYLGLYCEROL; VALINE;

ADULT; AGED; ALLELE; ARTICLE; CARDIOVASCULAR RISK; CONTROLLED STUDY; CORONARY ARTERY ATHEROSCLEROSIS; CORRELATION ANALYSIS; DISEASE COURSE; DNA POLYMORPHISM; GENE EXPRESSION REGULATION; GENE MUTATION; GENETIC VARIABILITY; HOMOZYGOTE; HUMAN; INFLAMMATION; INTRON; ISCHEMIC HEART DISEASE; LIPID BLOOD LEVEL; LIPID METABOLISM; MAJOR CLINICAL STUDY; MALE; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL;

AGED; ALLELES; AMINO ACID SUBSTITUTION; ANTILIPEMIC AGENTS; ARTERIOSCLEROSIS; CLINICAL TRIALS; COHORT STUDIES; COMORBIDITY; CORONARY ARTERIOSCLEROSIS; CORONARY ARTERY BYPASS; DISEASE PROGRESSION; FINLAND; GEMFIBROZIL; GENE FREQUENCY; GENETIC PREDISPOSITION TO DISEASE; GREAT BRITAIN; HUMANS; INTRONS; LIPIDS; MALE; MIDDLE AGED; POLYMORPHISM, GENETIC; PROSPECTIVE STUDIES; RECEPTORS, CYTOPLASMIC AND NUCLEAR; RISK ASSESSMENT; TRANSCRIPTION FACTORS;

EID: 0037177197     PISSN: 00097322     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.CIR.0000012145.80593.25     Document Type: Article

References (36)

1. Atherosclerosis - An inflammatory disease
2. Activation of a member of the steroid hormone receptor superfamily by peroxisome proliferators
3. Fatty acids, eicosanoids, and hypolipidemic agents identified as ligands of peroxisome proliferator-activated receptors by coactivator-dependent receptor ligand assay
4. Peroxisome proliferator-activated receptor-alpha activators regulate genes governing lipoprotein metabolism, vascular inflammation and atherosclerosis
5. Tissue distribution and quantification of the expression of mRNAs of peroxisome proliferator-activated receptors and liver X receptor-alpha in humans: No alteration in adipose tissue of obese and NIDDM patients
6. Expression of peroxisome proliferator-activated receptor alpha (PPAR alpha) in primary cultures of human vascular endothelial cells
7. Activation of human aortic smoothmuscle cells is inhibited by PPARα but not by PPARγ activators
8. Activation of proliferator-activated receptors alpha and gamma induces apoptosis of human monocyte-derived macrophages
9. CLA-I/SR-BI is expressed in atherosclerotic lesion macrophages and regulated by activators of peroxisome proliferator activated receptors
10. 9-Cis retinoic acid induces monocyte chemoattractant protein-1 secretion in human monocytic THP-1 cells
11. Peroxisome proliferator-activated receptor activators inhibit thrombin-induced endothelin-I production in human vascular endothelial cells by inhibiting the activator protein-1 signaling pathway
12. Peroxisome proliferator-activated receptor activators target human endothelial cells to inhibit leukocyte-endothelial cell interaction
13. PPARα activators inhibit cytokine-induced vascular cell adhesion molecule-I expression in human endothelial cells
14. Activation of PPARalpha or gamma reduces secretion of matrix metalloproteinase 9 but not interleukin 8 from human monocytic THP-1 cells
15. PPAR-alpha and PPAR-gamma activators induce cholesterol removal from human macrophage foam cells through stimulation of the ABCA1 pathway
16. PPARα agonists inhibit tissue factor expression in human monocytes and macrophages
17. PPARα activators inhibit tissue factor expression and activity in human monocytes
18. Peroxisome proliferator-activated receptor alpha negatively regulates the vascular inflammatory gene response by negative cross-talk with transcription factors NF-kappaB and AP-1
19. Peroxisome proliferator-activated receptor alpha activation modulates cellular redox status, represses nuclear factor-kappaB signaling, and reduces inflammatory cytokine production in aging
20. Effects of fenofibrate on plasma cytokine concentrations in patients with atherosclerosis and hyperlipo-proteinemia IIb
21. The PPARalpha-leukotriene B4 pathway to inflammation control
22. Oxidative stress as a regulator of gene expression in the vasculature
23. Bezafibrate has an antioxidant effect: Peroxisome proliferator-activated receptor alpha is associated with Cu2+, Zn2+-superoxide dismutase in the liver
24. Fibrates, dyslipoproteinaemia and cardiovascular disease
25. Variation in the PPARα gene is associated with altered function in vitro and plasma lipid concentrations in type II diabetic subjects
26. The human peroxisome proliferator-activated receptor a gene: Identification and functional characterization of two natural allelic variants
27. Prevention of the angiographic progression of coronary and vein-graft atherosclerosis by gemfibrozil after coronary bypass surgery in men with low levels of HDL cholesterol: Lopid Coronary Angiography Trial (LOCAT) Study Group
28. Increased activation of the haemostatic system in men at high risk of fatal coronary heart disease
29. Associations between lipoproteins and the progression of coronary and vein-graft atherosclerosis in a controlled trial with gemfibrozil in men with low baseline levels of HDL cholesterol
30. Accuracy and precision of quantitative arteriography in the evaluation of coronary artery disease after coronary bypass surgery. A validation study
31. cDNA cloning, chromosomal mapping, and functional characterization of the human peroxisome proliferator activated receptor
32. Molecular scanning of the human PPARα gene: Association of the L162V mutation with hyperapobetali-poproteinemia
33. Mutation screening of the PPARalpha gene in type 2 diabetes associated with coronary heart disease
34. Genetic determinants of the response to bezafibrate treatment in the Lower Extremity Arterial Disease Event Reduction (LEADER) trial
35. Peroxisome proliferator-activated receptors in inflammation control
36. PPARalpha deficiency reduces insulin resistance and atherosclerosis in apoE-null mice